• Brefeldin A: ATPase Inhibitor for Vesicle Transport & ER ...

  2026-02-25

  Brefeldin A (BFA) stands as a gold-standard tool for dissecting vesicle transport and ER stress pathways, enabling researchers to precisely manipulate protein trafficking and apoptosis in cancer models. APExBIO’s high-purity BFA empowers workflows ranging from basic mechanistic studies to advanced translational research, with protocol-driven optimizations and troubleshooting strategies that set it apart.

• Reactive Oxygen Species Assay Kit (DHE): Precision ROS De...

  2026-02-24

  The Reactive Oxygen Species Assay Kit (DHE) enables sensitive and quantitative ROS detection in living cells. Using a dihydroethidium (DHE) probe, this kit provides robust intracellular superoxide measurement, supporting oxidative stress assay and apoptosis research. APExBIO's validated workflow ensures high specificity for redox signaling pathway studies.

• Capecitabine: Fluoropyrimidine Prodrug for Tumor-Targeted...

  2026-02-24

  Capecitabine is a fluoropyrimidine prodrug widely used in preclinical oncology research for modeling tumor-specific drug activation and apoptosis. Its selective conversion to 5-fluorouracil in tumor tissue enhances chemotherapy precision and supports advanced assembloid workflows.

• EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rea...

  2026-02-23

  EPZ5676 is a potent and selective DOT1L histone methyltransferase inhibitor, offering nanomolar activity and >37,000-fold selectivity for MLL-rearranged leukemia models. Its robust inhibition of H3K79 methylation and validated cytotoxicity make it a gold-standard tool for epigenetic regulation and leukemia research.

• Capecitabine in Preclinical Oncology: Mechanisms, Stromal...

  2026-02-23

  Explore Capecitabine, a leading fluoropyrimidine prodrug, with a unique focus on its mechanistic action, stromal cell modulation, and advanced applications in assembloid models. This in-depth article offers new insights for preclinical oncology and tumor-targeted drug delivery.

• L1023 Anti-Cancer Compound Library: Scenario-Driven Solut...

  2026-02-22

  This article delivers a scenario-driven, evidence-based analysis of the L1023 Anti-Cancer Compound Library (SKU L1023) for biomedical researchers facing real-world challenges in cell-based anti-cancer assays. Drawing on recent literature and vendor comparisons, it demonstrates how SKU L1023 empowers high-throughput screening, ensures data reproducibility, and supports advanced oncology target validation.

• Oteseconazole (VT-1161): Mechanistic Insight, Translation...

  2026-02-21

  This thought-leadership article synthesizes mechanistic, experimental, and translational perspectives on Oteseconazole (VT-1161), a tetrazole CYP51 inhibitor redefining antifungal therapy for Candida infections—including fluconazole-resistant strains. Integrating recent scientific advances and strategic recommendations, the article provides translational researchers with actionable guidance for leveraging Oteseconazole (VT-1161) in experimental and clinical development settings, while situating the compound within the evolving antifungal therapeutic landscape.

• Oteseconazole (VT-1161): Tetrazole CYP51 Inhibitor for Ta...

  2026-02-20

  Oteseconazole (VT-1161) is a highly selective tetrazole CYP51 inhibitor, demonstrating potent antifungal activity against Candida species, including fluconazole-resistant strains. It offers improved clinical safety by minimizing drug-drug interactions and is FDA-approved for the prevention of recurrent vulvovaginal candidiasis. This dossier provides detailed, evidence-based insights for researchers and clinicians.

• Gastrin I (human): Mechanistic Precision and Translationa...

  2026-02-20

  Explore how Gastrin I (human) elevates GI research by uniting mechanistic clarity with translational impact. This article decodes the biological rationale for using this CCK2 receptor agonist, validates its power in advanced in vitro organoid systems, and offers strategic guidance for researchers aiming to bridge the gap between discovery and clinic.

• Brefeldin A (BFA): Strategic Disruption of ER Stress Path...

  2026-02-19

  Explore how Brefeldin A (BFA), a gold-standard ATPase and vesicle transport inhibitor from APExBIO, provides translational researchers with a uniquely powerful tool for interrogating endoplasmic reticulum (ER) stress, protein trafficking, and apoptosis in cancer models. This article synthesizes mechanistic insights, competitive benchmarking, and strategic recommendations, with special attention to the emerging role of N-recognins UBR1 and UBR2 in protein quality control. Go beyond conventional applications to unlock new experimental and therapeutic possibilities.

• EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rea...

  2026-02-19

  EPZ5676 is a highly potent and selective DOT1L histone methyltransferase inhibitor, widely used in MLL-rearranged leukemia research. As a competitive SAM inhibitor with nanomolar activity and over 37,000-fold selectivity, it enables robust, reproducible assays for H3K79 methylation inhibition and acute leukemia cytotoxicity.

• Capecitabine (SKU A8647): Reliable Solutions for Advanced...

  2026-02-18

  This article addresses core laboratory challenges in cell viability, apoptosis, and tumor modeling assays, showcasing how Capecitabine (SKU A8647) from APExBIO delivers reproducible, data-backed results. Drawing on recent advances in assembloid models and vendor benchmarks, it guides researchers in optimizing protocols, interpreting outcomes, and selecting high-quality reagents for preclinical oncology studies.

• Gastrin I (human): Mechanistic Precision and Strategic Ho...

  2026-02-18

  This thought-leadership article explores the transformative role of Gastrin I (human) as both a mechanistic probe and strategic tool for translational researchers. By situating this validated CCK2 receptor agonist within the evolving landscape of gastrointestinal physiology studies—including advanced organoid modeling and pharmacokinetic research—the piece delivers actionable guidance, competitive analysis, and a visionary outlook for GI disorder investigation and drug development. Anchored by recent advances in stem cell-derived intestinal organoid systems, the article demonstrates how APExBIO’s high-purity Gastrin I (human) elevates experimental fidelity and unlocks new translational possibilities.

• LY2109761: Selective TβRI/II Kinase Inhibitor for Advance...

  2026-02-17

  LY2109761 stands out as a potent, selective TGF-β receptor type I and II dual inhibitor, empowering researchers to dissect TGF-β signaling with unprecedented precision. From suppressing pancreatic cancer metastasis to enhancing radiosensitivity in glioblastoma, its robust inhibition of Smad2/3 phosphorylation unlocks new experimental and translational opportunities.

• Capecitabine (A8647): Mechanistic, Selective Fluoropyrimi...

  2026-02-17

  Capecitabine is a fluoropyrimidine prodrug designed for selective tumor activation and robust apoptosis induction in cancer research. Its conversion to 5-fluorouracil (5-FU) enables precise evaluation of chemotherapy selectivity, particularly in preclinical models of colon and hepatocellular carcinoma. This article synthesizes mechanistic evidence, workflow integration best practices, and key limitations for optimal use in advanced tumor-stroma and assembloid research.

14676 records 7/979 page Previous Next First page 上5页 678910 下5页 Last page